» Articles » PMID: 12576426

Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2003 Feb 11
PMID 12576426
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Underestimation of disease severity is a major problem confronting the successful clinical management of non-small cell lung cancer. Recent advances in molecular biological substaging may provide an opportunity to identify those patients with the most aggressive forms of the disease, but there is a continuing need for accurate markers of disease relapse and survival.

Experimental Design: In our present study, immunohistochemical analyses of a retrospective database of pathologic specimens were used to demonstrate that the EphA2 receptor kinase is frequently overexpressed in NSCLC.

Results: Initial presentation with high levels of EphA2 predicts subsequent survival, overall relapse, and site of relapse. Specifically, high levels of EphA2 in the primary tumor predict brain metastases, whereas low levels of EphA2 relate to disease-free survival or contralateral lung metastasis.

Conclusions: These data suggest that EphA2 may provide a molecular marker to identify and predict patients who have isolated brain metastases. Moreover, the high levels of EphA2 in lung cancer may provide an opportunity for therapeutic targeting.

Citing Articles

Theranostics using Zr/Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2).

Watabe T, Iwasawa T, Kimura H, Shirakami Y, Naka S, Kaneda K Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39934299 DOI: 10.1007/s00259-025-07139-9.


Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance.

Zhang Y, Shi R, Meng R, Lin S, Zheng M World J Gastrointest Oncol. 2024; 16(9):3781-3797.

PMID: 39350985 PMC: 11438782. DOI: 10.4251/wjgo.v16.i9.3781.


Targeting the EphA2 pathway: could it be the way for bone sarcomas?.

Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y Cell Commun Signal. 2024; 22(1):433.

PMID: 39252029 PMC: 11382444. DOI: 10.1186/s12964-024-01811-7.


Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics.

Liu J, Yuan Q, Chen X, Yang Y, Xie T, Zhang Y Sci Rep. 2024; 14(1):17650.

PMID: 39085301 PMC: 11291735. DOI: 10.1038/s41598-024-68385-9.


Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.

Liu J, Cai Y, He Y, Xu J, Tian S, Li Z BMC Cancer. 2024; 24(1):123.

PMID: 38267913 PMC: 10809508. DOI: 10.1186/s12885-024-11875-w.